Neurana Pharmaceuticals, Inc. is a privately held biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the back. In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and included participation from New Leaf Venture Partners, H.I.G. BioHealth, and Longitude Capital.

NEURANA TEAM

The team at Neurana Pharmaceuticals is comprised of experienced biotech executives committed to bringing a novel therapy to patients suffering from muscle spasms

CRAIG THOMPSON
President & Chief Executive Officer
RANDALL KAYE,MD
Chief Medical Officer
KATHY SCOTT
Chief Financial Officer

CATHERINE BRISSON – Regulatory Affairs

JIM GALLAGHER – CMC, Manufacturing

JOHNNA HANNAH – Corporate Development

SANAM ARA VAUGHAN – Clinical Operations

TOM YONKER – Project Management

 
 

INVESTORS

Sinnova.jpg
HIG_BioHealthPartners_Web.jpg
Longitude-Logo.png
NLVP_logo_header.png
161_MagnaSci_Ventures.jpg
Hale-BioPharma-Ventures-Logo.jpg